Capital Analysts LLC
RPRX icon

Capital Analysts LLC’s Royalty Pharma RPRX Stock Holding History

Capital Analysts LLC’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$119K Buy
+2,046
New +$121K ﹤0.01% 807

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital Analysts LLC's RPRX Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Royalty Pharma (RPRX) in Q3 2026: 2,046 shares worth $119K. The stake represents ﹤0.01% of the portfolio and ranks #807 among its holdings.

573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Capital Analysts LLC held 2,046 shares of Royalty Pharma worth $119K as of Q3 2026.
  • Royalty Pharma was a new Capital Analysts LLC position in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #807 holding.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.